Imeik Technology Development Co - Asset Resilience Ratio

Latest as of December 2025: 24.18%

Imeik Technology Development Co (300896) has an Asset Resilience Ratio of 24.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Imeik Technology Development Co for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥2.15 Billion
≈ $315.23 Million USD Cash + Short-term Investments

Total Assets

CN¥8.91 Billion
≈ $1.30 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Imeik Technology Development Co's Asset Resilience Ratio has changed over time. See 300896 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Imeik Technology Development Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Imeik Technology Development Co.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.15 Billion 24.18%
Total Liquid Assets CN¥2.15 Billion 24.18%

Asset Resilience Insights

  • Good Liquidity Position: Imeik Technology Development Co maintains a healthy 24.18% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Imeik Technology Development Co Industry Peers by Asset Resilience Ratio

Compare Imeik Technology Development Co's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
Medical Instruments & Supplies 9.08%
Vizionfocus Inc.
TW:4771
Medical Instruments & Supplies 5.07%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 4.42%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 51.82%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 6.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%
Trajan Group Holdings Ltd
AU:TRJ
Medical Instruments & Supplies 0.23%
Osteopore Ltd
AU:OSX
Medical Instruments & Supplies 43.09%

Annual Asset Resilience Ratio for Imeik Technology Development Co (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Imeik Technology Development Co.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 24.18% CN¥2.15 Billion
≈ $315.23 Million
CN¥8.91 Billion
≈ $1.30 Billion
-10.32pp
2024-12-31 34.50% CN¥2.88 Billion
≈ $421.12 Million
CN¥8.34 Billion
≈ $1.22 Billion
+16.93pp
2023-12-31 17.57% CN¥1.20 Billion
≈ $176.20 Million
CN¥6.85 Billion
≈ $1.00 Billion
+6.33pp
2022-12-31 11.24% CN¥703.69 Million
≈ $102.97 Million
CN¥6.26 Billion
≈ $915.82 Million
+4.22pp
2021-12-31 7.03% CN¥370.51 Million
≈ $54.22 Million
CN¥5.27 Billion
≈ $771.47 Million
-10.99pp
2020-12-31 18.01% CN¥841.57 Million
≈ $123.15 Million
CN¥4.67 Billion
≈ $683.61 Million
+11.10pp
2016-12-31 6.92% CN¥21.71 Million
≈ $3.18 Million
CN¥313.86 Million
≈ $45.93 Million
-5.34pp
2015-12-31 12.25% CN¥21.16 Million
≈ $3.10 Million
CN¥172.64 Million
≈ $25.26 Million
-7.15pp
2014-12-31 19.41% CN¥20.43 Million
≈ $2.99 Million
CN¥105.29 Million
≈ $15.41 Million
--
pp = percentage points

About Imeik Technology Development Co

SHE:300896 China Medical Instruments & Supplies
Market Cap
$5.09 Billion
CN¥34.81 Billion CNY
Market Cap Rank
#3543 Global
#546 in China
Share Price
CN¥115.05
Change (1 day)
-0.96%
52-Week Range
CN¥112.46 - CN¥201.00
All Time High
CN¥570.69
About

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate compos… Read more